Validation for a drug class, and for Sanofi

Several big pharma companies have made significant investments in selective oestrogen degraders, or Serds, and the most advanced, Sanofi, is about to see whether this has been worth it. Its project, amcenestrant, will yield breast cancer data from the pivotal Ameera-3 trial in the coming weeks.